This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

AstraZeneca, Handa fail to get out of US antitrust case over Seroquel XR

( April 2, 2025, 23:31 GMT | Official Statement) -- MLex Summary: AstraZeneca, Handa Pharmaceuticals and Par Pharmaceuticals must face US antitrust claims over an alleged reverse payment concerning Seroquel XR, a federal judge ruled. District Judge Colm F. Connolly said that an expert opinion and record evidence provide a sufficient basis for a reasonable juror to find that AstraZeneca would have agreed in an alternative settlement agreement to grant Handa a license to the relevant patent beginning earlier than November 2016.See attached file. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections